8-K: TuHURA Biosciences and Kintara Therapeutics Announce Positive Phase 1b Trial Results and Merger Plans

TuHURA Biosciences and Kintara Therapeutics announced positive results from a Phase 1b trial of IFx-2.0, a personalized cancer vaccine, and detailed their planned merger.

Summary

• TuHURA Biosciences and Kintara Therapeutics have announced positive results from a Phase 1b clinical trial of TuHURA's IFx-2.0 cancer vaccine.
• The trial focused on patients with advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) who were resistant to checkpoint inhibitor therapy.
• 80% of ICI-naive MCC patients achieved a durable response (complete or partial) after IFx-2.0 treatment and subsequent rechallenge with an anti-PD(L)-1 checkpoint inhibitor.
• The average duration of response was 25 months, with some responses ongoing at 19 and 23 months.
• Overall, 63% of MCC patients showed durable disease control after IFx-2.0 treatment and rechallenge with standard of care ICI agents.
• The Phase 1b study met its primary safety objective, with 80% completion of planned therapy.
• TuHURA and Kintara also announced a planned merger, with the combined company expected to operate under the name TuHURA Biosciences, Inc. and trade on Nasdaq under the ticker HURA.
• The merger is expected to close in the third quarter of 2024, subject to customary closing conditions and stockholder approval.
• TuHURA also secured $31 million in financing in conjunction with the merger agreement.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results and a strategic merger, indicating a strong outlook for the combined company. The high response rate and duration of response are particularly encouraging.

Positives

• The IFx-2.0 cancer vaccine demonstrated a high response rate in patients with advanced MCC who were resistant to checkpoint inhibitors.
• The duration of response was significant, with an average of 25 months and some responses ongoing.
• The Phase 1b trial met its primary safety objective, indicating the treatment is well-tolerated.
• The planned merger will combine the expertise and resources of TuHURA and Kintara to advance a diversified oncology pipeline.
• The $31 million financing will provide capital for the combined company's operations.

Negatives

• The merger is subject to customary closing conditions, including stockholder approval, which introduces some uncertainty.
• The merger could be delayed or terminated if conditions are not met.
• The document contains forward-looking statements that are subject to risks and uncertainties, and actual results could differ materially.

Risks

• The merger may not be completed if conditions are not met, including failure to obtain stockholder approval.
• There are uncertainties regarding the timing of the merger and the ability of both companies to complete the transaction.
• The combined company may face challenges in estimating operating expenses and merger-related costs.
• The merger could negatively impact business relationships and operating results.
• Legal proceedings related to the merger could arise.
• The combined company may face challenges in protecting intellectual property rights.
• The combined company may face competitive responses to the merger.
• The combined company may face unexpected costs, charges, or expenses.
• The combined business may not be successful.
• Legislative, regulatory, political, and economic developments could impact the combined company.

Future Outlook

The combined company will focus on advancing TuHURA's personalized cancer vaccine(s) and first-in-class bi-functional Antibody Drug Conjugates. A Phase 3 trial of IFx-2.0 as an adjunctive therapy with Keytruda is planned to begin enrollment in the second half of 2024. The merger is expected to close in the third quarter of 2024.

Management Comments

• Dr. James Bianco, Chief Executive Officer of TuHURA, commented that IFx-2.0 demonstrated the ability to overcome resistance to ICI in 63% of patients with advanced MCC.
• Dr. Bianco also noted the group of most interest were the seven patients with ICI naive, advanced MCC, who showed a significant response to IFx-2.0 treatment.

Industry Context

The announcement highlights the growing interest in personalized cancer vaccines and overcoming resistance to checkpoint inhibitors, which are significant challenges in the immuno-oncology field. The merger reflects a trend of companies combining resources to accelerate drug development and expand their pipelines.

Comparison to Industry Standards

• The 80% response rate in ICI-naive MCC patients is very promising compared to typical outcomes with checkpoint inhibitors alone in resistant cancers.
• The 25-month average duration of response is also notable, as many cancer immunotherapies struggle to achieve such durable results.
• While specific comparisons to other personalized cancer vaccines are difficult without detailed data, the results suggest IFx-2.0 has the potential to be a competitive therapy in this space.
• The planned Phase 3 trial will be crucial in further validating these results and comparing IFx-2.0 to standard of care treatments like Keytruda.

Stakeholder Impact

• Shareholders of both Kintara and TuHURA will be impacted by the merger, with the potential for increased value in the combined company.
• Employees of both companies will be affected by the merger, with potential changes in roles and responsibilities.
• Patients with advanced MCC and cSCC may benefit from the development of IFx-2.0 and other therapies.
• The merger could impact the competitive landscape for other companies in the immuno-oncology space.

Next Steps

• Kintara and TuHURA will seek stockholder approval for the proposed merger.
• The companies will work to satisfy the remaining closing conditions for the merger.
• TuHURA plans to initiate a Phase 3 registration-directed clinical trial of IFx-2.0 in the second half of 2024.
• The combined company will focus on advancing TuHURA's personalized cancer vaccine(s) and first-in-class bi-functional Antibody Drug Conjugates.

Key Dates

Keywords

IFx-2.0, cancer vaccine, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, checkpoint inhibitor, immunotherapy, merger, TuHURA Biosciences, Kintara Therapeutics, clinical trial, oncology, biopharmaceutical